Compare ASE Technology Holding Co Ltd (ASX) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Danaher Corporation — how do they compare? ASE Technology Holding Co Ltd trades at $41.59 (market cap $92.88B), while Danaher Corporation trades at $199.4 (market cap $140.88B). The key difference: Danaher Corporation is the larger of the two by market cap, and ASE Technology Holding Co Ltd pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| ASX | DHR | |
|---|---|---|
Market Cap | $92.88B | $140.88B |
Sector | Technology | Health |
52-Week High | $45.12 | $242.05 |
52-Week Low | $9.50 | $161.91 |
Enterprise Value | $97.32B | $153.66B |
Dividend Yield | 0.98% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.
Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.
Danaher (DHR) trades at $199.05, up 1.57% today, with strong technical momentum as price approaches resistance at $200. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.06 exceeding expectations of $1.94, though revenue growth remains modest at 2.9% year-over-year. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment, supporting positive analyst sentiment.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) and a $214.73 consensus target offering 7.9% upside, but faces risks from elevated valuation (P/E 38.58) and slowing profit margins. The stock's near-term direction will depend on Q2 2026 earnings delivery and biotechnology segment performance amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
